ConductScience.org, home

Paper41301162

Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions.

Gao Y and 4 others. Bioengineering (Basel), 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions. Papers, record 41301162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301162

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions.
PubMed
Journal
Bioengineering (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-11-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gao YYang
2Wang JPJian-Ping
3Hong DFDe-Fei
4Yang CChang
5Naranmandura HHuahttps://orcid.org/0000-0003-0799-2340

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82172599National Natural Science Foundation of ChinaPubMed
82170143National Natural Science Foundation of ChinaPubMed
82370191National Natural Science Foundation of ChinaPubMed
82200160National Natural Science Foundation of ChinaPubMed

Source PubMed

Download CSV of grants

References156

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135133380Engineered mesenchymal stem cell-derived exosomes with high CXCR4 levels for targeted siRNA gene therapy against cancer.Nanoscale2022https://conductscience.org/library/papers/35133380PubMed
237752117Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37752117PubMed
336652132Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis.Apoptosis2023https://conductscience.org/library/papers/36652132PubMed
439806451Emerging role of exosomes in cancer therapy: progress and challenges.Mol Cancer2025https://conductscience.org/library/papers/39806451PubMed
533527831Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells.Mol Pharm2021https://conductscience.org/library/papers/33527831PubMed
640696139Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.Leukemia2025https://conductscience.org/library/papers/40696139PubMed
732483419CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway.Theranostics2020https://conductscience.org/library/papers/32483419PubMed
836261831Tumor buster - where will the CAR-T cell therapy 'missile' go?Mol Cancer2022https://conductscience.org/library/papers/36261831PubMed
938402155Ultrasonic microbubbles promote mesenchymal stem cell homing to the fibrotic liver via upregulation of CXCR4 expression.Cell Div2024https://conductscience.org/library/papers/38402155PubMed
1039261846Engineering exosomes derived from TNF-α preconditioned IPFP-MSCs enhance both yield and therapeutic efficacy for osteoarthritis.J Nanobiotechnology2024https://conductscience.org/library/papers/39261846PubMed
1140683482Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights.Pharmacol Res2025https://conductscience.org/library/papers/40683482PubMed
1234929349Management of hepatocellular carcinoma recurrence after liver transplantation.Ann Hepatol2022https://conductscience.org/library/papers/34929349PubMed
1319654411Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties.Blood2009https://conductscience.org/library/papers/19654411PubMed
1436817457Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model.Front Immunol2023https://conductscience.org/library/papers/36817457PubMed
1540703618Amphiphilic lipid-peptide engineered placenta-derived mesenchymal stem cells for liver fibrosis treatment.Asian J Pharm Sci2025https://conductscience.org/library/papers/40703618PubMed
1636100944Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential.Mol Cancer2022https://conductscience.org/library/papers/36100944PubMed
1726073566Mesenchymal stem cells and adaptive immune responses.Immunol Lett2015https://conductscience.org/library/papers/26073566PubMed
1838299924Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off-the-shelf versatile tumor delivery vehicle.Med Res Rev2024https://conductscience.org/library/papers/38299924PubMed
1934838121Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.J Hematol Oncol2021https://conductscience.org/library/papers/34838121PubMed
2039636740Energy Stress-Induced circEPB41(2) Promotes Lipogenesis in Hepatocellular Carcinoma.Cancer Res2025https://conductscience.org/library/papers/39636740PubMed

See all 156 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42861321Drug Delivery Systems for Hepatocellular Carcinoma: Bridging Pathophysiological Barriers and Advanced Nanomedicine Strategies.Drug Des Devel Ther2026https://conductscience.org/library/papers/42861321PubMed
42338608Rearming mesenchymal stem cells with engineering strategies to combat cancer.Front Immunol2026https://conductscience.org/library/papers/42338608PubMed
41847179Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.Int J Nanomedicine2026https://conductscience.org/library/papers/41847179PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41301162

GET https://conductscience.org/api/papers/v1/41301162/references?page=2